Business Context and Reporting Period
Company: AngioDynamics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: February 29, 2008 (Fiscal Third Quarter)
Business Overview: AngioDynamics designs, develops, and markets medical devices for minimally invasive, image-guided procedures to treat peripheral vascular disease and oncology. The company operates as a single segment. A significant portion of recent growth is attributed to the January 2007 acquisition of RITA Medical Systems, Inc.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Feb 29, 2008 |
Nine Months Ended Feb 29, 2008 |
Nine Months Ended Mar 3, 2007 |
|---|---|---|---|
| Net Sales | $40,725 | $119,748 | $71,372 |
| Gross Profit | $25,318 | $73,274 | $42,119 |
| Gross Margin % | 62.2% | 61.2% | 59.0% |
| Operating Income (Loss) | $7,603 | $15,915 | $(15,257) |
| Net Income (Loss) | $4,890 | $10,370 | $(12,053) |
| Diluted EPS | $0.20 | $0.43 | $(0.73) |
| Cash from Operations | N/A | $20,132 | $3,437 |
| Total Cash & Equivalents | $43,646 | $43,646 | $38,052 |
| Total Debt (Current + Long-term) | $17,200 | $17,200 | $17,430 |
Note: Total Debt includes $10.04 million current portion and $7.16 million long-term portion as of Feb 29, 2008.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 52% ($14.0 million) in the quarter and 68% ($48.4 million) for the nine-month period compared to the prior year. This growth is primarily driven by the inclusion of RITA Medical Systems products.
- Profitability Turnaround: The company reported a net income of $4.9 million for the quarter, a significant improvement from a net loss of $16.4 million in the prior year quarter. The prior year loss was heavily impacted by a $12.1 million in-process R&D charge related to the RITA acquisition and a $9.6 million litigation provision.
- Operating Expenses: R&D expenses decreased 72% in the quarter due to the absence of the prior year's acquisition-related charge. Sales and marketing expenses increased 46% due to the expanded sales force from the RITA acquisition.
- Litigation Impact: The company recorded a $3.2 million pre-tax gain on the settlement of the Diomed litigation, reducing the litigation provision from approximately $10.2 million to $7.0 million.
Outlook, Risks, and Contingencies
- Guidance: Management expects R&D expenditures to remain in the range of 8% to 9% of net sales for fiscal 2008. No specific revenue guidance was provided in this text.
- Acquisition Contingency (Oncobionic): The company has a pending acquisition of Oncobionic, Inc., subject to successful human use tests for irreversible electroporation (IRE) technology. Results are expected within three months. A $5.0 million non-refundable deposit has been paid. If tests fail, the company may terminate the agreement but lose the deposit.
- Litigation Risks:
- Diomed: Settled for $7.0 million; funds are restricted cash.
- VNUS Medical Technologies: Pending patent infringement lawsuit. Potential loss range is estimated between $0 and $10 million. Trial anticipated in 2008.
- biolitec: AngioDynamics is seeking indemnification from biolitec for defense costs in the Diomed and VNUS actions. Biolitec has counter-claimed for approximately $1.6 million in defense costs.
- Liquidity: The company believes current cash, investments, and operating cash flow are sufficient for the next 12 months. However, significant future acquisitions may require additional equity or debt financing.
Key Facts for Investor Verification
- Settlement Terms: Verify the final payment schedule and any remaining liabilities associated with the $7.0 million Diomed settlement.
- Oncobionic Trial Results: Monitor the outcome of the human use tests for IRE technology, as this determines the $20 million remaining purchase price obligation.
- VNUS Litigation Exposure: Assess the potential financial impact of the VNUS lawsuit, with a stated risk range of up to $10 million.
- Debt Maturity: Note that $9.7 million in convertible notes assumed from RITA mature on August 5, 2008, with conversion dependent on stock price performance.
- Restricted Cash: Confirm the utilization of the $10.98 million in restricted cash, which includes funds set aside for the Diomed settlement and facility expansion.